CAMBRIDGE, Mass. (AP) -- Biotechnology company Alkermes Inc. said Thursday it swung to a fiscal 2008 fourth-quarter loss on charges for cutting jobs and shuttering a facility in the wake of partner Eli Lilly & Co.'s decision to end development of their inhaled insulin.
